Headquartered in Cambridge, MA·Fiscal year ends December·NASDAQ: RLAY·relaytx.com
About Relay Therapeutics
Relay Therapeutics is a clinical-stage, small molecule precision medicine company developing therapies for cancer and genetic disease. Its Dynamo platform combines computational and experimental approaches to drug protein targets that have been intractable or inadequately addressed; the platform enabled the discovery of zovegalisib, which the company describes as the first known allosteric, pan-mutant, isoform-selective PI3Kα inhibitor. Zovegalisib is being evaluated with fulvestrant in the Phase 3 ReDiscover-2 trial in PI3Kα-mutated, CDK4/6 pre-treated HR+/HER2- advanced breast cancer. A frontline Phase 3 trial combining zovegalisib with Pfizer's CDK4-selective atirmociclib is planned for early 2027. Zovegalisib is also in the Phase 1/2 ReInspire trial for PIK3CA-driven vascular anomalies. The company estimates zovegalisib could address about 140,000 PI3Kα-mutated HR+/HER2- breast cancer patients and 170,000 PI3Kα-driven vascular anomaly patients per year in the U.S. The pipeline also includes programs for NRAS-driven solid tumors, Fabry disease, and a late-stage preclinical mutant-selective TIE2 inhibitor for venous malformations. Relay has licensed lirafugratinib to Elevar Therapeutics, which received FDA full approval as LYRFIGTU for FGFR2-altered cholangiocarcinoma. The company is building commercial capabilities ahead of potential launches. It currently has no product revenue, with occasional license revenue, and ended Q3 2026 with about $848.6 million in cash, cash equivalents and investments, which it expects to fund operations into 2029. Updated
A $848.6 million cash pile funds operations into 2029, well past the mid-2027 Phase 3 enrollment completion for zovegalisib in breast cancer. The loss narrowed versus consensus even with one-time lease termination costs from exiting One Kendall Square. Vascular anomalies data lands at ASH on December 14.
Clinical-stage biotech is one of the few corners of the market where a sub-$30 share price genuinely matters: small-cap oncology names can re-rate violently around a single Phase 3 readout or FDA…